Now Reading: Lupin sales jump 33% as pharma majors pivot to India, emerging markets
-
01
Lupin sales jump 33% as pharma majors pivot to India, emerging markets
Lupin sales jump 33% as pharma majors pivot to India, emerging markets
Lupin posted a 33.3% year-on-year sales jump to ₹8,217 crore in Q1 FY27, with EBITDA rising 42.8% to ₹2,580 crore and profit after tax up 16% to ₹1,417 crore. The company attributed…
The Story in Brief
Lupin posted a 33.3% year-on-year sales jump to ₹8,217 crore in Q1 FY27, with EBITDA rising 42.8% to ₹2,580 crore and profit after tax up 16% to ₹1,417 crore. The company attributed the strong start to robust growth across the US, India, other developed markets and emerging markets, along with continued profitability improvement.
The results come amid a broader shift in the pharma sector. According to The Hindu Business Line, Sun Pharma, Aurobindo Pharma and Dr Reddy’s Laboratories showed divergent performances. Sun Pharma’s sales rose 10% to ₹15,184 crore, driven by India formulations and innovative medicines, while its US formulations fell 9.7%. Aurobindo posted 16.3% revenue growth to ₹9,150 crore. Dr Reddy’s, however, saw revenue drop 5.6% to ₹8,071 crore and profit plunge 69% due to lack of lenalidomide sales and a ₹240-crore semaglutide provision. The Business Line notes that domestic branded formulations, innovative medicines and emerging markets are increasingly cushioning Indian drugmakers against US market volatility.
The Indian Opinion
The narrative that Indian pharma is still hostage to the US generics market is wearing thin. This quarter’s diverging results show the real story: companies that built branded formulations and innovative medicines at home are outperforming those still leaning on US commodity sales. The real test will be whether Sun Pharma’s innovative medicines margin can hold as generic headwinds persist, and whether Dr Reddy’s can replace the lost lenalidomide revenue within two quarters.
Sources (2): businesstoday.in, thehindubusinessline.com
This story was synthesised by AI from the 2 sources linked above.
Updated: this story now draws on 2 sources.
